Galectin Therapeutics Inc, GALT Securities Lawsuit

Company:	Galectin Therapeutics Inc,
Ticker Symbol:	GALT
Class Period:	Jan-6-14 to Jul-28-14
Date Filed:	Aug-11-14
Lead Plaintiff Deadline:	Oct-10-14
Court:	District of Nevada
Allegations:

Los Angeles, CA: A securities class action lawsuit representing investors of Galectin Therapeutics Inc. ("Galectin"or the "Company") (NASDAQ:GALT), has been filed in the United States District Court for the District of Nevada on behalf of a class (the "Class") comprising purchasers of Galectin securities between January 6, 2014 and July 28, 2014, inclusive (the "Class Period").

Galectin is a development stage company engaged in the research and development of therapies for fibrotic disease and cancer.

The Complaint alleges that defendants misrepresented or failed to disclose that the Company paid a stock promotions firm for a misleading promotional campaign touting Galectin stock, and that the Company' experimental drug GR-MD-02, which was being developed for the treatment of fatty liver disease, showed little difference from a placebo in its Phase 1 study.

If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.

Galectin Therapeutics Inc, GALT Securities Fraud Legal Help

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible Galectin Therapeutics Inc, securities class action lawsuit. Please click the link below to submit your complaint for a free evaluation.